Journal Watch · Journal of Controlled Release · 2026

Reversing immunotherapy resistance in cold tumors by weaponizing pyroptosis with a dual-payload nanotuner.

Overall, our findings establish a novel therapeutic paradigm for reversing ICB resistance via orchestrated pyroptosis amplification.

Hu J, Lu Y, Tan Z et al.Journal of Controlled Release3 min readPharma relevance 80/100

DOI: 10.1016/j.jconrel.2026.115116PMID: 42314991Study type: research study

TL;DR

Overall, our findings establish a novel therapeutic paradigm for reversing ICB resistance via orchestrated pyroptosis amplification.

Key findings

  • This dual-pathway engagement enhances the release of pro-inflammatory cytokines and remodels the tumor immune microenvironment.
  • As a result, this nano-pyroptosis inducer overcomes resistance to anti-PD-1 therapy, triggering potent systemic anti-tumor immunity and significantly inhibiting tumor growth.
  • Overall, our findings establish a novel therapeutic paradigm for reversing ICB resistance via orchestrated pyroptosis amplification.

What they did

Here, we report a sialic acid-functionalized lipid nanoparticle (LNP) that co-delivers GSDME mRNA and a self-assembling small molecule (1541B) as a potent pyroptosis amplifier. Delivered GSDME mRNA bypasses epigenetic silencing and replenishes the pyroptotic substrate, while 1541B self-assembles intracellularly into nanofibers that directly activate caspase-3, cleaving GSDME to initiate non-canonical pyroptosis. Moreover, these nanofibers disrupt mitochondrial function, leading to caspase-1-mediated GSDMD cleavage, thereby amplifying pyroptotic cell death via the canonical pathway.

Full abstract (original)

Background: The efficacy of immune checkpoint blockade (ICB) is often constrained by insufficient tumor antigenicity and consequent weak immune activation. Among immunogenic cell death (ICD) modalities, gasdermin-mediated pyroptosis presents a promising strategy to counteract this limitation and potentiate ICB. However, it remains challenging to engineer nanoplatforms that reliably induce pyroptosis via coordinated activation of multiple pathways.

What they did: Here, we report a sialic acid-functionalized lipid nanoparticle (LNP) that co-delivers GSDME mRNA and a self-assembling small molecule (1541B) as a potent pyroptosis amplifier. Delivered GSDME mRNA bypasses epigenetic silencing and replenishes the pyroptotic substrate, while 1541B self-assembles intracellularly into nanofibers that directly activate caspase-3, cleaving GSDME to initiate non-canonical pyroptosis. Moreover, these nanofibers disrupt mitochondrial function, leading to caspase-1-mediated GSDMD cleavage, thereby amplifying pyroptotic cell death via the canonical pathway.

Results & conclusions: This dual-pathway engagement enhances the release of pro-inflammatory cytokines and remodels the tumor immune microenvironment. As a result, this nano-pyroptosis inducer overcomes resistance to anti-PD-1 therapy, triggering potent systemic anti-tumor immunity and significantly inhibiting tumor growth. Overall, our findings establish a novel therapeutic paradigm for reversing ICB resistance via orchestrated pyroptosis amplification.

Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.115116 · PubMed 42314991.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, targeted oncology / immuno-oncology, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · targeted oncology / immuno-oncology · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Controlled Release study find?

Overall, our findings establish a novel therapeutic paradigm for reversing ICB resistance via orchestrated pyroptosis amplification.

What type of study is this?

It is a research study, published in Journal of Controlled Release in 2026. Here, we report a sialic acid-functionalized lipid nanoparticle (LNP) that co-delivers GSDME mRNA and a self-assembling small molecule (1541B) as a potent pyroptosis amplifier.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jconrel.2026.115116. PubMed ID: 42314991. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Hu J, Lu Y, Tan Z et al.. Reversing immunotherapy resistance in cold tumors by weaponizing pyroptosis with a dual-payload nanotuner.. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.115116.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/reversing-immunotherapy-resistance-in-cold-tumors-by-weaponizing-pyropto-115116/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides